Abstract
Significant clinical benefit has been demonstrated in patients with ACS undergoing percutaneous coronary intervention with optimal medical therapy as part of an early invasive strategy. Bare-metal stents (BMS) have been shown to improve clinical outcomes compared with balloon angioplasty, but are also associated with restenosis and the need for repeat revascularization. Drug-eluting stents (DES) have subsequently been developed to reduce the occurrence of restenosis; however, there is debate about their true efficacy and long-term safety. In this review, clinical trials investigating outcomes with DES compared with BMS are discussed in the setting of ACS.
| Original language | English |
|---|---|
| Pages (from-to) | 109-113 |
| Number of pages | 5 |
| Journal | Acute Coronary Syndromes |
| Volume | 10 |
| Issue number | 3 |
| State | Published - 2011 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine